CONGRESS ABSTRACT

Background: sub-phenotyping patients with cardiogenic shock (CS) through a non-traditional clustering method may represent a significant step forward in precision medicine, enhancing clinical outcomes in this heterogeneous and high-mortality condition. We aimed to apply an unsupervised machine learning approach integrating clinical and imaging data (including advanced echocardiography) to identify…

Background: Recent ESC guidelines introduced a new treatment paradigm for HFrEF, with a novel four pillar therapeutic approach comprising ACE-I/ARBs/ARNIs, Beta-blockers, MRAs, and SGLT2i. Furthermore, these guidelines for the first time give a Class IA recommendation for Empagliflozin and Dapagliflozin in HFmrEF and HFpEF. Evaluation of transferability of RCTs…

Background: cardiogenic shock (CS) remains a major complication of acute myocardial infarction (AMI), contributing significantly to morbidity and mortality. Temporary mechanical circulatory support (t-MCS) has gained prominence in CS management, also serving as a bridge during high-risk percutaneous coronary interventions (PCI). While the DanGer Shock Trial demonstrated the superiority of…

We report the case of a 16-year-old patient, admitted at Bambino Gesù Hospital for cardiogenic shock. He was a competitive athlete with history of sporadic episodes of myalgias and elevated CPK. One week before he had an episode of headache and prolonged fasting during which he performed intense workout….